MedTrace Logo

Effects of Oxygen Supply After Lung Isolation in Thoracic Surgery

NCT05946707 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2024-03-12

No results posted yet for this study

Summary

The goal of this randomized clinical trial is to compare a liberal versus restrictive oxygen supply (fraction of inspired oxygen, FiO2) strategy in patients scheduled for thoracic surgery requiring one-lung ventilation during lung isolation. The primary and secondary outcome parameters are:

* oxygenation of the blood after 30 minutes of one-lung ventilation, assessed by PaO2/FiO2 ratio
* time to lung collapse after start of one-lung ventilation

Participants in the control goup will receive an oxygen content of 100% before lung isolation, which will be subsequently decreased to achieve normoxia or mild hyperoxia (PaO2 of 75-120 mmHg).

The intervention group will receive the previous, during two-lung ventilation set, oxygen content and after lung isolation oxygen supply will be increased to secure adequate oxygenation of the blood (PaO2 75-120 mmHg) during one-lung ventilation.

The investigators hypothesize, that a higher fraction of inspired oxygen may impede hypoxic pulmonary vasoconstriction of the collapsed lung and thus decrease overall oxygenation performance during one-lung ventilation. Secondary endpoint will be the time to lung collapse, as a lower fraction of inspired oxygen and thus a higher nitrogen content may impede lung collapse.

Conditions

  • Mechanical Ventilation
  • Thoracic Surgery
  • One-Lung Ventilation

Interventions

DRUG

restrictive oxygen supply

Oxygen supply will be limited to guarantee normoxia at the beginning of OLV.

DRUG

liberal oxygen supply

Oxygen supply will be maximized to 100% at the beginning of OLV

Sponsors & Collaborators

  • Medical University Innsbruck

    lead OTHER

Principal Investigators

  • Patrick Spraider, MD · Medical University of Innsbruck, Department of Anesthesiology and Intensive Care Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-19
Primary Completion
2024-03-07
Completion
2024-03-07

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05946707 on ClinicalTrials.gov